Residency · Residency · Critical Care

Non-Invasive Ventilation and High-Flow Nasal Cannula

High-Flow Nasal Cannula (HFNC)

Mechanism of Action

High-flow nasal cannula has emerged as a transformative respiratory support modality that bridges the gap between conventional oxygen therapy and non-invasive positive pressure ventilation. The system delivers heated gas at 37 degrees Celsius and fully humidified at 100 percent relative humidity at flow rates up to 60 liters per minute through specially designed nasal prongs. This high flow rate produces several physiological effects that collectively improve respiratory function. By meeting or exceeding the patient's peak inspiratory flow demand, HFNC eliminates entrainment of room air that occurs with conventional low-flow oxygen devices, enabling reliable and precise FiO2 delivery. The high flow generates a flow-dependent positive pressure effect of approximately 1 cmH2O per 10 liters per minute of flow when the mouth is closed, though this effect diminishes substantially with mouth opening. Continuous high-flow washout of the nasopharyngeal dead space improves CO2 clearance and effective alveolar ventilation, reducing the work of breathing beyond what would be expected from supplemental oxygen alone. The delivery of fully conditioned gas eliminates the metabolic cost of heating and humidifying inspired air, further reducing the work of breathing, and the warm, humidified flow improves mucociliary clearance and provides pneumatic splinting of the upper airway.

Equipment and Settings

HFNC nasal cannula prongs should fit snugly within the nares without occluding them to allow adequate positive pressure generation while permitting exhalation. Flow rate is typically initiated at 30 to 40 liters per minute and titrated upward to 40 to 60 liters per minute as tolerated by the patient. FiO2 is set to match the prior oxygen requirement and titrated to the target SpO2. The temperature is standardly set at 37 degrees Celsius but can be reduced to 34 to 35 degrees if the patient reports discomfort from the warm flow. The ROX index, calculated as SpO2 divided by FiO2 divided by respiratory rate, has been validated as a bedside prediction tool for HFNC success: a ROX index of 4.88 or greater at 12 hours predicts HFNC success, while a ROX index below 2.85 at 2 hours predicts failure and should prompt consideration of escalation to intubation.

Clinical Evidence

The FLORALI trial by Frat and colleagues in 2015 compared HFNC against standard oxygen therapy and non-invasive ventilation in patients with acute hypoxemic, non-hypercapnic respiratory failure. The primary outcome of intubation rate showed no significant difference overall, but a post-hoc subgroup analysis of patients with PaO2/FiO2 of 200 or below revealed a lower intubation rate with HFNC at 35 percent compared to 58 percent with standard oxygen and 50 percent with NIV. Most notably, 90-day mortality was significantly lower with HFNC compared to both standard oxygen and NIV. The RECOVERY-RS trial during the COVID-19 pandemic demonstrated that CPAP reduced intubation compared to HFNC in patients with acute hypoxemia from COVID-19. For post-extubation support, the HIGH trial of 2019 established HFNC as non-inferior to NIV for preventing reintubation in low-risk patients.

Indications

The primary indications for HFNC include acute hypoxemic respiratory failure of the de novo, non-hypercapnic type; post-extubation respiratory support for low-risk patients; pre-oxygenation before intubation, as supported by the PREOXYFLOW and FELLOW trials; acute respiratory failure in immunocompromised patients, where HFNC is preferable to invasive mechanical ventilation when possible; and comfort care in patients declining intubation. HFNC is relatively contraindicated in hypercapnic respiratory failure, where the insufficient pressure support provided by nasal cannula flow alone is inadequate to augment ventilation and correct hypercarbia.

<image>Anatomical cross-section of the upper airway showing HFNC mechanism of action. Sagittal view of nasal cavity, nasopharynx, and upper trachea with HFNC prongs in nares. Arrows showing: (1) high-flow gas washing out CO2-rich dead space gas from nasopharynx (shown as colored gradient from blue fresh gas to red CO2-laden gas being displaced); (2) pneumatic splinting of soft palate and pharynx preventing collapse; (3) flow generating positive nasopharyngeal pressure (pressure gauge annotation showing ~3-5 cmH2O at 50 L/min with mouth closed). Inset showing heated humidified gas at 37 degrees C with water vapor particles. Adjacent panel comparing FiO2 delivery: conventional nasal cannula at 6 L/min showing dilution with room air versus HFNC at 50 L/min exceeding inspiratory demand.</image>

Non-Invasive Positive Pressure Ventilation (NIV)

Modes of Delivery

Non-invasive ventilation is delivered in two principal modes, each with distinct physiological effects and clinical applications. Continuous positive airway pressure applies a single level of continuous pressure throughout the respiratory cycle, which recruits collapsed alveoli, increases functional residual capacity, and reduces intrapulmonary shunt. CPAP does not directly augment tidal volume or assist ventilation and is therefore a purely oxygenation-supporting modality, typically applied at pressures of 5 to 15 cmH2O. Bilevel positive airway pressure, or BiPAP, provides two pressure levels: an inspiratory positive airway pressure (IPAP) and an expiratory positive airway pressure (EPAP). The effective pressure support, equal to IPAP minus EPAP, augments tidal volume and assists ventilation, while the EPAP component provides the same alveolar recruitment and oxygenation benefits as CPAP. Typical starting settings are IPAP of 10 to 20 cmH2O and EPAP of 5 to 10 cmH2O. BiPAP thus provides both oxygenation support through EPAP and ventilatory assistance through the pressure support component.

Interfaces

The choice of interface significantly impacts both the efficacy and tolerance of NIV. The oronasal or full-face mask is the most commonly used interface in the acute setting because it eliminates mouth leak, which can substantially reduce the effectiveness of nasal masks. Nasal masks are better tolerated but lose efficacy when patients breathe through their mouths. Total face masks that cover the entire face are useful for patients with facial anatomy challenges and may reduce claustrophobia. The helmet interface, which encloses the entire head, has generated considerable interest following studies by Patel and colleagues in 2016 and the HENIVOT trial suggesting lower intubation rates compared to face mask NIV. The helmet reduces air leak, allows eating and drinking during therapy, and distributes pressure over a larger surface area, reducing the risk of facial pressure injuries. The general principle is that interface selection impacts both efficacy and patient tolerance, and trialing different interfaces should be attempted before concluding that NIV has failed.

Physiological Effects

The hemodynamic effects of NIV are therapeutically important, particularly in cardiogenic pulmonary edema. Increased intrathoracic pressure reduces preload by decreasing venous return, which is beneficial in the volume-overloaded state. Simultaneously, positive intrathoracic pressure reduces left ventricular transmural pressure, effectively reducing afterload and decreasing LV wall stress. Together with alveolar recruitment from PEEP/EPAP and ventilatory assistance from pressure support, these effects make NIV a powerfully synergistic intervention in acute heart failure. In patients with COPD and auto-PEEP, applied EPAP offsets the threshold load imposed by intrinsic PEEP, reducing the inspiratory work required to trigger the ventilator and substantially decreasing the overall work of breathing.

Evidence-Based Indications

Strong Evidence (Standard of Care)

NIV for acute exacerbations of COPD with respiratory acidosis represents one of the most well-established evidence-based therapies in critical care. The landmark trial by Brochard and colleagues in 1995 demonstrated that NIV reduced the intubation rate from 74 percent to 26 percent compared to standard care, with a number needed to treat of approximately 4 for preventing intubation. Subsequent meta-analyses have confirmed reductions in intubation, ICU mortality, and hospital length of stay. NIV is indicated when the pH is between 7.25 and 7.35 with respiratory acidosis; patients with pH below 7.25 are more likely to fail NIV and may require immediate intubation, though a brief trial of NIV can be attempted with close monitoring. The key failure indicator is lack of pH improvement within 1 to 2 hours, along with persistent tachypnea or worsening encephalopathy.

For acute cardiogenic pulmonary edema, both CPAP and BiPAP are effective. The 3CPO trial of 2008 compared CPAP versus BiPAP versus standard oxygen therapy and found that both NIV modes reduced dyspnea and improved metabolic parameters compared to oxygen alone, without a mortality difference between the NIV groups. An earlier concern about increased myocardial infarction rates with BiPAP, raised by a small study by Mehta in 1997, was not confirmed in subsequent larger studies. NIV for cardiogenic pulmonary edema can be initiated in the pre-hospital setting and has demonstrated a mortality benefit when applied early.

Moderate Evidence

In immunocompromised patients with acute respiratory failure, the evidence for NIV has evolved. While the study by Hilbert and colleagues in 2001 demonstrated reduced intubation and mortality with NIV compared to standard oxygen therapy, more recent data from Lemiale and colleagues in the 2015 Efraim study showed no significant difference between early NIV and oxygen alone. HFNC may be the preferred first-line modality in this population due to better tolerance, lower dead space, and easier application.

For post-extubation failure prevention in high-risk patients, NIV has demonstrated significant benefit. High-risk criteria include age over 65, congestive heart failure, APACHE II score above 12 on extubation day, more than one failed spontaneous breathing trial, and multiple comorbidities. Trials by Nava in 2005 and Ferrer in 2006 demonstrated that preventive NIV reduced reintubation rates and ICU mortality in these patients. A critical distinction must be drawn between preventive NIV, applied immediately upon extubation in high-risk patients, which is beneficial, and therapeutic NIV, applied after post-extubation respiratory failure has developed, which was demonstrated by Esteban and colleagues in 2004 to delay necessary reintubation and increase mortality.

NIV can also facilitate extubation in selected COPD patients who have failed spontaneous breathing trials. Meta-analysis by Burns and colleagues demonstrated that direct extubation to NIV in this population reduces mortality and ventilator-associated pneumonia, though this strategy requires an experienced team with close monitoring capability.

Contraindications to NIV

Absolute contraindications include cardiac or respiratory arrest, inability to protect the airway, an uncooperative or severely agitated patient, facial surgery or trauma precluding mask fit, high aspiration risk, and life-threatening hypoxemia requiring immediate intubation. Relative contraindications include hemodynamic instability, multiple organ failure, excessive secretions, recent upper gastrointestinal surgery, and severe encephalopathy with a GCS below 8.

<image>Decision algorithm for respiratory support selection in acute respiratory failure. Top entry point: "Acute respiratory failure — assess etiology and severity." First branch: Hypercapnic (COPD, neuromuscular) vs. Hypoxemic (de novo). Hypercapnic pathway: pH <7.25 → intubate; pH 7.25-7.35 → NIV (BiPAP, IPAP 12-20, EPAP 5-8); reassess at 1-2 hours (improved pH → continue, worsening → intubate). Hypoxemic pathway: Cardiogenic pulmonary edema → CPAP or BiPAP; De novo hypoxemic → HFNC first-line (flow 40-60 L/min), assess ROX index at 2, 6, 12 hours; if ROX <2.85 at 2h or <4.88 at 12h → consider intubation; Immunocompromised → HFNC preferred, NIV alternative. Include intubation criteria at each decision point: RR >35, accessory muscle use, pH <7.25, GCS deterioration, hemodynamic instability.</image>

NIV in the Acute Setting: Practical Management

Initiation Protocol

NIV should be initiated with systematic attention to interface selection and pressure titration. The oronasal mask is the most appropriate initial choice in the acute setting. Starting pressures should be low, with IPAP at 10 cmH2O and EPAP at 5 cmH2O, to promote tolerance and allow the patient to acclimate. FiO2 is titrated to achieve a target SpO2 of 92 to 96 percent. IPAP is then increased by 2 cmH2O every 10 to 15 minutes based on tidal volume, respiratory rate, and patient comfort, targeting a tidal volume of 6 to 8 mL/kg ideal body weight and a respiratory rate reduction to below 25 per minute. Maximum IPAP is typically 20 to 25 cmH2O, beyond which leak and gastric insufflation become increasingly problematic. Proper mask fit with minimal leak is essential, but excessive strap tension must be avoided as it leads to pressure injuries, particularly over the nasal bridge, which occurs in 10 to 20 percent of patients receiving prolonged NIV.

Monitoring and Failure Criteria

Close monitoring during the first 1 to 2 hours of NIV application is critical and cannot be overemphasized. An arterial blood gas should be obtained at 1 to 2 hours to assess response, and failure of pH to improve, or worsening of pH, constitutes an indication for intubation. Clinical signs of NIV failure include persistent tachypnea above 35 per minute, accessory muscle use, inability to handle secretions, agitation or somnolence, and hemodynamic instability. Validated predictors of NIV failure include APACHE II score above 25, GCS below 11, pH below 7.25 after 1 hour of NIV, and PaO2/FiO2 below 146 after 1 hour. The single most important principle is to intubate early when NIV is failing, as delayed intubation after NIV failure is consistently associated with increased mortality.

Complications

The complications of NIV include mask-related pressure injuries particularly at the nasal bridge and forehead, claustrophobia, eye irritation from air leak, gastric insufflation requiring nasogastric tube placement during prolonged use, aspiration risk, patient-ventilator dyssynchrony related to leak-induced autocycling and trigger failure, and rare pneumothorax. The most dangerous complication is delayed intubation: the reassurance provided by improved oxygen saturation on NIV can mask progressive respiratory failure, leading to catastrophic decompensation when NIV finally fails.

NIV vs. HFNC: Comparative Considerations

Advantages of HFNC Over NIV

HFNC offers superior tolerance and comfort, allowing patients to eat, drink, talk, and expectorate during therapy. It eliminates the interface-related pressure injuries that are a significant morbidity of NIV. HFNC can be delivered continuously without the periodic removal required by NIV masks, provides better dead space washout, and delivers more reliable FiO2 than NIV systems prone to air leak.

Advantages of NIV Over HFNC

NIV provides true ventilatory assistance through pressure support augmentation of tidal volume, delivers substantially higher PEEP levels of up to 15 to 20 cmH2O compared to the approximately 5 cmH2O achievable with HFNC, and is essential for hypercapnic respiratory failure where ventilatory augmentation is the primary therapeutic goal. NIV is also superior for acute cardiogenic pulmonary edema due to its preload and afterload reduction effects.

Choosing Between NIV and HFNC

The choice between these modalities is guided by the underlying pathophysiology. For hypercapnic failure from COPD exacerbation, NIV is the standard of care and HFNC is not an adequate substitute. For cardiogenic pulmonary edema, NIV or CPAP is the standard of care. For de novo hypoxemic respiratory failure, HFNC is the preferred first-line modality based on FLORALI data. For post-extubation support, HFNC is appropriate for low-risk patients based on the HIGH trial, while NIV is preferred for high-risk patients based on the trials by Nava and Ferrer. For immunocompromised patients, HFNC is generally preferred due to its better tolerance and comfort profile. In de novo hypoxemic respiratory failure, a particular concern with NIV is that it may generate excessively large tidal volumes driven by the patient's strong respiratory effort, potentially worsening lung injury through patient self-inflicted lung injury, which further supports the preference for HFNC in this setting.

Key Clinical Pearls

• HFNC provides approximately 1 cmH2O PEEP per 10 L/min of flow (mouth closed) — it is NOT equivalent to true CPAP/PEEP
• The ROX index (SpO2/FiO2 divided by RR) is the best validated bedside tool for predicting HFNC failure — calculate at 2, 6, and 12 hours
• NIV is life-saving in COPD exacerbation with respiratory acidosis — it is the single most effective therapy and should not be delayed
• NIV should NOT be used to treat established post-extubation respiratory failure — it delays intubation and increases mortality
• Helmet NIV may be superior to face mask NIV in hypoxemic respiratory failure (Patel et al.) but requires specific ventilator settings and expertise
• The most dangerous complication of NIV/HFNC is delayed intubation — close monitoring in the first 1-2 hours and early intubation for non-responders is essential
• In de novo hypoxemic respiratory failure, NIV may generate large tidal volumes that worsen lung injury (P-SILI) — HFNC is preferred in this setting

References

1. Frat JP, Thille AW, Mercat A, et al. High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. N Engl J Med. 2015;372(23):2185-2196.
2. Brochard L, Mancebo J, Wysocki M, et al. Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease. N Engl J Med. 1995;333(13):817-822.
3. Gray A, Goodacre S, Newby DE, et al. Noninvasive ventilation in acute cardiogenic pulmonary edema. N Engl J Med. 2008;359(2):142-151.
4. Patel BK, Wolfe KS, Pohlman AS, et al. Effect of noninvasive ventilation delivered by helmet vs face mask on the rate of endotracheal intubation in patients with acute respiratory distress syndrome. JAMA. 2016;315(22):2435-2441.
5. Roca O, Caralt B, Messika J, et al. An index combining respiratory rate and oxygenation to predict outcome of nasal high-flow therapy. Am J Respir Crit Care Med. 2019;199(11):1368-1376.

Read this lecture as Markdown